Nelson F, Lebrun-Frénay C, Boyko A, et al. Long-term outcomes in patients with progressive forms of relapsing MS treated with teriflunomide: real-world evidence. AAN 2018, S8.004.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose